ContraVir leadership brings deep experience in the development and commercialization of targeted antiviral therapies for indications of important unmet need.
Gary S. Jacob, Ph.D.
Chairman and Director
Gary S. Jacob, Ph.D. has served as Chairman and Director of ContraVir since May 2013. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob currently serves as a director of Trovagene, Inc., a public diagnostics company and a director and Chief Executive Officer of Synergy Pharmaceuticals Inc. since July 2008. Dr. Jacob has over twenty-five years of experience in the pharmaceutical and biotechnology industries across multiple disciplines. Learn More >>
John P. Brancaccio, C.P.A.
John P. Brancaccio, a retired C.P.A., has served as a Director of our company since May 2013. Since April 2004, Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. Learn More >>
Timothy M. Block, Ph.D.
Timothy M. Block, Ph.D., has served as a Director of our company since October 2013. Dr. Block currently serves as Co-founder and President of the Hepatitis B Foundation (HBF) and its Baruch S. Blumberg Institute (formerly called the Institute for Hepatitis and Virus Research), the nation’s leading nonprofit organizations dedicated to improving the lives of those affected worldwide through research, education and patient advocacy. He also serves as President and CEO of the Pennsylvania (PA) Biotechnology Center. Learn More >>
Arnold Lippa, Ph.D.
Dr. Lippa has been Executive Chairman of the Board of Cortex Pharmaceuticals Inc., since March 2013, and was appointed Chief Scientific Officer in August 2015. Previously, he served as Chief Executive Officer and President. He is also Chairman of the Board of Xintria Pharmaceutical Corporation, which he co-founded in 2006. Dr. Lippa is a Managing Member and founder of T Morgen Capital LLC, which is an investment and management company specializing in the creation and management of biomedical companies. Learn More >>
Thomas H. Adams, Ph.D.
Thomas H. Adams, Ph.D. currently serves as Chairman of the Board for Trovagene Inc., a director of Synergy Pharmaceuticals, Inc. and a director and Chief Technology Officer of IRIS International, Inc. Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to 2006, when Leucadia was acquired by IRIS. Dr. Adams has significant public-company experience serving as a director of Invitrogen from 2000 to 2002. Learn More >>
Robert Foster, B.Sc. (Pharm), Pharm.D., Ph.D.
Chief Executive Officer
Dr. Foster brings over 30 years of pharmaceutical and biotech experience to Contravir. Prior to Contravir, he was CEO and Founder of Ciclofilin Pharmaceuticals Inc. which merged with ContraVir. Prior to Ciclofilin Pharmaceuticals, he founded Isotechnika Pharma Inc. He was Chairman and CEO of Isotechnika (TSX:ISA) for 21 years. Dr. Foster was founding CEO, and later CSO, of Aurinia (NASDAQ:AUPH) after Isotechnika acquired Aurinia. During his tenure with Isotechnika, Dr. Foster, together with a core team, discovered the immunosuppressive drug voclosporin. Learn More >>